ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VRAY
CUSIPN/A
Phone440-703-3210
Debt
Debt-to-Equity Ratio1.17
Current Ratio3.33
Quick Ratio2.64
Price-To-Earnings
Trailing P/E Ratio-8.33
Forward P/E Ratio-11.38
P/E GrowthN/A
Sales & Book Value
Annual Sales$34.04 million
Price / Sales19.11
Cash FlowN/A
Price / CashN/A
Book Value$0.03 per share
Price / Book288.33
Profitability
EPS (Most Recent Fiscal Year)($1.04)
Net Income$-72,170,000.00
Net Margins-83.84%
Return on Equity-353.05%
Return on Assets-46.00%
Miscellaneous
Employees139
Outstanding Shares75,210,000
Market Cap$703.93 million
Viewray (NASDAQ:VRAY) Frequently Asked Questions
What is Viewray's stock symbol?
Viewray trades on the NASDAQ under the ticker symbol "VRAY."
How were Viewray's earnings last quarter?
Viewray Inc (NASDAQ:VRAY) posted its quarterly earnings data on Friday, August, 3rd. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.09. The firm earned $16.44 million during the quarter, compared to analyst estimates of $15.97 million. Viewray had a negative return on equity of 353.05% and a negative net margin of 83.84%. The company's revenue for the quarter was up 2255.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.15) EPS. View Viewray's Earnings History.
When is Viewray's next earnings date?
What price target have analysts set for VRAY?
6 equities research analysts have issued 1 year price targets for Viewray's shares. Their predictions range from $10.00 to $14.00. On average, they anticipate Viewray's share price to reach $12.5833 in the next twelve months. This suggests a possible upside of 45.0% from the stock's current price. View Analyst Price Targets for Viewray.
What is the consensus analysts' recommendation for Viewray?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viewray.
What are Wall Street analysts saying about Viewray stock?
Here are some recent quotes from research analysts about Viewray stock:
- 1. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on shares of VRAY and our 12-month price target of $13. VRAY has succeeded in bringing an MRI linear accelerator (linac) to the market when its larger competitors could not. VRAY’s differentiated technology has the potential to change radiation therapy longer term, but VRAY’s commercial launch is only in its infancy. Positive early clinical data are driving physician interest, but the price of the system comes at a significant premium (~50%) to existing linacs. VRAY, like many small capital equipment companies, comes with a good amount of risk, but we think the momentum is building." (10/3/2018)
- 2. BTIG Research analysts commented, "PT to $14 from $10 VRAY preannounced 2Q rev and reported gross orders of $34.6M Friday coming in in line with consensus. Shares were probably pressured by GMs of ~0% due to one-time issues and expected cash use for the year being increased $10M. We continue to expect VRAY to require additional funding by 1H19. We like the new mgmt team’s track record both as operators and sellers of companies and expect an improvement in commercial execution. That said we felt the stock had overrun a bit to near $13 and would have moved to Neutral but with shares pulling back now still see them compelling. We are raising our out year PT to $14. While we still see VRAY as compelling we have learned quite a bit about potential new competition in MagnetTx (Private), whom we recently visited in Edmonton." (8/7/2018)
- 3. Mizuho analysts commented, "We were at the Advanced Applications of MR-Guided Radiotherapy Symposium in Amsterdam on March 16th, 2018. The event was very well attended with approximately 200 people; most were potential customers who showed strong interest in ViewRay’s MRIdian. We highlight our key takeaways from the conference and additional insights into the MRI Linac below. Overall, we maintain our view that ViewRay has leadership in real time imaging guided LINAC today." (4/19/2018)
Are investors shorting Viewray?
Viewray saw a increase in short interest in the month of September. As of September 28th, there was short interest totalling 16,723,336 shares, an increase of 20.7% from the September 14th total of 13,858,513 shares. Based on an average daily trading volume, of 1,506,200 shares, the short-interest ratio is currently 11.1 days. Approximately 26.1% of the company's shares are sold short. View Viewray's Current Options Chain.
Who are some of Viewray's key competitors?
Some companies that are related to Viewray include CONMED (CNMD), NxStage Medical (NXTM), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), Electrocore (ECOR), BioLife Solutions (BLFS), Vision Sciences (CGNT), Semler Scientific (SMLR), Rockwell Medical (RMTI), Helius Medical Technologies (HSDT), Fonar (FONR), Second Sight Medical Products (EYES), Zynex (ZYXI) and Edap Tms (EDAP).
When did Viewray IPO?
(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.
Who are Viewray's major shareholders?
Viewray's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Pennsylvania Trust Co (0.13%). Company insiders that own Viewray stock include Ajay Bansal, Fmr Llc, Henry A Mckinnell, International Ltd Fosun, James F Dempsey and Orbimed Advisors Llc. View Institutional Ownership Trends for Viewray.
Which major investors are buying Viewray stock?
VRAY stock was purchased by a variety of institutional investors in the last quarter, including Pennsylvania Trust Co. Company insiders that have bought Viewray stock in the last two years include Ajay Bansal, Henry A Mckinnell and International Ltd Fosun. View Insider Buying and Selling for Viewray.
How do I buy shares of Viewray?
Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viewray's stock price today?
One share of VRAY stock can currently be purchased for approximately $8.68.
How big of a company is Viewray?
Viewray has a market capitalization of $703.93 million and generates $34.04 million in revenue each year. The company earns $-72,170,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Viewray employs 139 workers across the globe.
What is Viewray's official website?
How can I contact Viewray?
Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]
MarketBeat Community Rating for Viewray (NASDAQ VRAY)
MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe VRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
